This study is first of its kind to comprehensively evaluate the effects of the SGLT2 inhibitor dapagliflozin on both hepatic steatosis and fibrosis using ultrasonography and transient elastography study and by analyzing the results of various noninvasive hepatic fibrosis scales in patients with DM2 and NAFLD. This evidence concerns the gene SLC5A2 and fatty liver disease.